Coexistence of two different mutations in codon 12 of the Kras gene in colorectal cancer: Report of a case supporting the concept of tumoral heterogeneity

GIUSEPPINA IMPROTA¹, ANGELA ZUPA¹, LUCIANA POSSIDENTE¹, ALFREDO TARTARONE², PIERNICOLA PEDICINI³, ANTONIO NAPPI³, SERGIO MOLINARI⁴, FILIPPO FRAGGETTA⁵ and GIULIA VITA⁶

¹Laboratory of Clinical Research and Molecular Diagnostics; Departments of ²Medical Oncology, ³Nuclear Medicine and Radiotherapy and ⁴Healthcare Management, IRCCS-CROB Hospital, Rionero In Vulture, Potenza; ⁵Department of Pathology, Cannizzaro Hospital, Catania; ⁶Department of Pathology, IRCCS-CROB Hospital, Rionero In Vulture, Potenza, Italy

Received December 18, 2012; Accepted March 7, 2013

DOI: 10.3892/ol.2013.1255

Abstract. Evaluation of the mutational status of KRAS is a crucial step for the correct therapeutic approach in treating advanced colorectal cancer as the identification of wild-type KRAS tumors leads to more specific and less toxic treatments for patients. Although several studies have highlighted the differences between primary and metastatic tumors, the possibility of two or more mutations in the same codon has seldom been reported. The present study reports an additional case of an advanced adenocarcinoma of the colon showing two somatic mutations (p.G12D and p.G12V) in the same codon (codon 12) of exon 2 of the KRAS gene, thus supporting the possibility of two differing clonal origins of the tumor. Although the clinical significance of multiple mutations remains unknown at present, based on the limited data available in the literature, this rare event appears to be associated with a more aggressive disease, as in the present case. This case report demonstrates the existence of intratumoral heterogeneity and the coexistence of distinct clones within a tumor that may have profound clinical implications for disease progression and therapeutic responses.

Introduction

Evaluation of the KRAS mutational status is a crucial step for the correct therapeutic approach in advanced colorectal cancer. According to well-established criteria, a molecular analysis of exon 2 (codons 12 and 13) is routinely performed in formalin-fixed, paraffin-embedded (FFPE) tissue and the identification of a wild-type (WT) KRAS tumor may lead to a more tumor-specific and less toxic treatment for the patient.

Numerous studies have demonstrated significant intratumoral heterogeneity, with spatially separated heterogeneous somatic mutations and chromosomal imbalances (1). With regard to colorectal cancer, several studies have highlighted the differences in the KRAS mutational status between primary and metastatic tumors within lymph nodes and visceral metastases or even different portions of the primary lesion (2), thus supporting the overall current theory of neoplastic heterogeneity (1,3). However, the possibility of two or more mutations in the same codon of the KRAS gene has seldom been reported in colorectal cancer and the real clinical impact of multiple mutations on patient prognosis has not yet been well studied and clarified (4-7).

The present study reports an additional case of the coexistence of two different mutations in codon 12 of the Kras gene in colorectal cancer: Report of a case supporting the concept of tumoral heterogeneity

Correspondence to: Dr Giuseppina Improta, Laboratory of Clinical Research and Molecular Diagnostics, IRCCS-CROB Hospital, 1 Via Padre Pio, Rionero In Vulture, Potenza I-74028, Italy E-mail: giuseppina.improta@gmail.com

Key words: KRAS, colorectal cancer, multiple mutations, tumoral heterogeneity
histological examination revealed a ypT3 adenocarcinoma, of
tumor regression grading (TRG) 3 with metastases in 1 out of
10 resected lymph nodes (ypT3pN1Mx TRG3). In October 2012, prior to starting the planned post-operative
chemotherapy, a CT scan revealed multiple liver metastases, although the carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19.9 values were normal. The patient began chemotherapy with 7.5 mg/kg bevacizumab daily and the XELOX regimen (130 mg/m² oxaliplatin daily + 2,000 mg/m² capecitabine on days 1-14). This treatment is ongoing.

Materials and methods. Prior to the mutation analysis, the patient provided informed written consent. A tissue sample from the primary tumor was obtained from the archives of the IRCCS-CROB Hospital. A section of this specimen, stained with hematoxylin and eosin, was observed by a pathologist to evaluate the percentage of cancer cells prior to performing a manual dissection of the tumor area. DNA extraction was performed using a QIAamp® DNA Mini kit (Qiagen, Hilden, Germany), and exon 2 (codons 12 and 13) of the KRAS gene was amplified by polymerase chain reaction (PCR) using the following designed primers: forward, 5'-GGTGGAGTATTGTAGTAGTGTAT-3' and reverse, 5'-AGAATGGTCCTGCACCAGTAA-3'. PCR was performed in a final volume of 25 µl under the following conditions: 1X buffer, 3 mmol/l magnesium chloride, 200 µmol/l deoxyribonucleotide phosphates (all from Applied Biosystems, manufactured by Roche, Branchburg, NJ, USA), 12.5 pmol of each primer (Sigma Aldrich, St. Louis, MO, USA), 200 ng/µl DNA and 1.5 U Taq DNA polymerase (Applied Biosystems manufactured by Roche). Following use of an initial melting temperature of 94°C for 2 min, the reaction mixture was subjected to 35 cycles of 94°C for 30 sec, 56°C for 30 sec and 65°C for 30 sec, followed by a final 72°C extension step for 2 min. Prior to sequencing, the PCR products were stained with ethidium bromide and visualized on a UV transilluminator following 2% gel electrophoresis. The PCR products were then sequenced using the BigDye Terminator v.1.1 sequencing kit (Applied BioSystems, Foster City, CA, USA) (8).

Results. The percentage of sample tumor cells was evaluated by the pathologist and estimated to be ~60%. The DNA quality was evaluated by spectrophotometer analysis and the A260/A280 ratio was 1.8. The coexistence of two mutations, p.G12D and p.G12V, in the same codon (codon 12) of the KRAS gene was observed by molecular biologists in two independent PCR products and demonstrated by sense and anti-sense sequence analysis of the fragments (Fig. 1). The DNA amplified sequence of the KRAS gene was compared with the wild-type KRAS sequence.

Discussion

Colorectal cancer is the third most commonly diagnosed type of cancer and the third leading cause of cancer mortality in males and females. With the development of drugs, including irinotecan and oxaliplatin, and targeted therapies, including cetuximab and bevacizumab therapy, the median survival has increased to >20 months. Several studies have shown that KRAS mutations in primary tumors predict resistance to anti-EGFR antibodies (9-11) and thus, only patients with wild-type KRAS tumors (~60% of patients) are eligible for anti-EGFR therapy. Although the results of the KRAS mutational analysis of the primary tumor usually match with the metastases, in a minority of cases (5-10%), the KRAS mutational status is heterogeneous between the primary tumor and metastases (2,12-15). These observations may reflect the increased genetic instability in cells that progressively acquire mutations or the presence of a heterogeneous group of neoplastic cells inside the tumor (16,17). In addition, few studies have observed the coexistence of more than one mutation in the KRAS gene within the same colorectal tumor, correlating this type of alteration with clinical and morphological features (4-7).

The present study reports a case of the coexistence of two mutations, p.G12D (GGT>GAT) and p.G12V (GGT>GTT), in the same codon of the KRAS gene, in the same selected tumor area, thus demonstrating the existence of intratumoral heterogeneity. Based on data in the literature, multiple mutations in the KRAS gene are infrequent, representing 2.1% of mutations in colorectal cancer (18). The majority of co-mutations in the KRAS gene affect only one codon (59%), mainly codon 12, although co-mutations may affect codons 12 and 13 simultaneously (18). The most frequently altered amino acid sequences involved in these co-mutations are GAT (in codon 12) and GAC (in codon 13) (18).

Due to the scarcity of data in the literature, the clinical implications and prognostic significance of multiple KRAS mutations remain unknown, although associations with
advanced clinical stage and aggressive clinical course have been reported (4-7,19). The present case was characterized by an aggressive clinical course with the development of early liver metastases despite the administration of neoadjuvant chemo-radiotherapy. Whether this aggressiveness was due to the coexistence of multiple mutations or a specific single mutation is, however, questionable.

It has been shown that not all KRAS mutations have the same prognostic relevance. A meta-analysis demonstrated that the p.G12V mutation at codon 12 in the KRAS gene increases the risk of recurrence or mortality in patients with colorectal cancer (17,20-21), unlike other KRAS mutations that have only a moderate, non-significant effect on overall survival (22). These data are consistent with experimental evidence showing that valine mutations produce proteins with different behavior compared with other mutated KRAS proteins (12). The lower affinity of GTP to p.G12D allows p.G12D to escape from the oncogenic GTP-bound state, whereas GTP that is tightly bound to p.G12V generates a more persistent, potentially oncogenic signal. Furthermore, differences in the effector region of p.G12D and p.G12V may modify interactions with downstream signaling molecules (12).

In the present case the coexistence of these two mutations, p.G12D and p.G12V, may have had an almost different clinical relevance on patient prognosis (20,22). The effect of various KRAS mutations on overall survival may be explained by the fact that the heterogeneity of the various KRAS mutations in colorectal cancer may differ in carcinogenic potential. This may justify the selection of a new clone with a p.G12V mutation and more aggressive behavior, along with the pre-existing p.G12D clone.

Therefore, it should be a great challenge to detect all mutations present in tumors. It has been suggested that a DNA tumoral mix obtained from different tumor areas may increase the detection rate of mutations, including multiple mutations (2,23). This is consistent with the current theory that tumors show significant intratumoral heterogeneity, characterized by separated heterogeneous somatic mutations and chromosomal aberrations (1). Such genetic heterogeneity may also cause heterogeneity in terms of radiosensitivity (24), with a strong impact on the choice of the most appropriate treatment option when the disease is treatable with radiotherapy alone or combined with chemotherapy or biological drugs (25,26).

In conclusion, the present study underlines the intratumoral heterogeneity, as supported by the current data (1,2) in which tumors may be polyclonal with a mixture of cell populations harboring varying mutations. The coexistence of distinct clones within a tumor may have profound clinical implications for disease progression and therapeutic responses. In particular, the present case appears to support the hypothesis that the presence of multiple mutations in codon 12 is associated with a more aggressive disease.

References
1. Gerlinger M, Rowan AJ, Horswell S, et al: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366: 883-892, 2012.
2. Baldus SE, Schaefer KL, Engers R, Hartleb D, et al: Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 16: 790-799, 2010.
3. Marusyk A and Polyak K: Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 1805: 105-117, 2010.
4. De Roock W, Pisseaux H, De Schutter J, et al: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19: 508-515, 2008.
5. Jönsson M, Ekstrand A, Edeking T, et al: Experiences from treatment-predictive KRAS testing; high mutation frequency in rectal cancers from females and concurrent mutations in the same tumor. BMC Clin Pathol 9: 8, 2009.
6. Moerkert P, Arends JW, van Driel M, et al: Type and number of Ki-ras point mutations relate to stage of human colorectal cancer. Cancer Res 54: 3376-3378, 1994.
7. Sameer AS, ul Rehman S, Pandith AA, et al: Molecular gate keepers succumb to mutation inactivation in colorectal cancer in Kashmiri population, revealing a high incidence area. Saudi J Gastroenterol 15: 244-252, 2009.
8. Sanger F, Nicklen S and Coulson AR: DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 74: 5463-5467, 1977.
9. Lièvre A, Bachet JB, Le Corre D, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995, 2006.
10. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1629-1634, 2008.
11. Karapetis CS, Khambata‑Ford S, Jonker DJ, et al: K‑ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757‑1765, 2008.
12. Al‑Mulla F, Going JJ, Sowden ET, et al: Heterogeneity of mutant versus wild‑type Ki‑ras in primary and metastatic colorectal carcinomas, and association of codon‑12 valine with early mortality. J Pathol 185: 130‑138, 1998.
13. Albanese I, Sciubetta AG, Migliavacca M, et al: Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki‑ras and p53 mutations. Biochem Biophys Res Commun 325: 784‑791, 2004.
14. Mancuso A, Sollami R, Recine F, et al: Patient with colorectal cancer with heterogeneous KRAS molecular status responding to cetuximab‑based chemotherapy. J Clin Oncol 28: e576‑e578, 2010.
15. Lamy A, Blanchard F, Le Pessot F, et al: Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls. Mod Pathol 24: 1090‑1100, 2011.
16. Bouchahda M, Karaboué A, Saffroy R, et al: Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. Cancer Chemother Pharmacol 66: 605‑609, 2010.
17. Andreyev HJ, Norman AR, Cunningham D, et al: Kirsten ras mutations in patients with colorectal cancer: the multicenter 'RASCAL' study. J Natl Cancer Inst 90: 675‑684, 1998.
18. Macedo MP, Andrade Lde B, Coudry R, et al: Multiple mutations in the Kras gene in colorectal cancer: review of the literature with two case reports. Int J Colorectal Dis 26: 1241‑1248, 2011.
19. Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406: 747‑752, 2000.
20. Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869‑10874, 2001.
21. Fialkow PJ: Clonal origin of human tumors. Annu Rev Med 30: 135‑143, 1979.
22. Winder T, Mündlein A, Rhomberg S, et al: Different types of K‑Ras mutations are conversely associated with overall survival in patients with colorectal cancer. Oncol Rep 21: 1283‑1287, 2009.
23. Richman SD, Chambers P, Seymour MT, et al: Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (cCRC) and cost-effectiveness of raf multiple sample testing. Anal Cell Pathol (Amst) 34: 61‑66, 2011.
24. Spitzner M, Emons G, Kramer F, et al: A gene expression signature for chemoradiosensitivity of colorectal cancer cells. Int J Radiat Oncol Biol Phys 78: 1184‑1192, 2010.
25. Pedicini P, Napni A, Strigari L, et al: Correlation between EGFr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma. Radiat Oncol 7: 143, 2012.
26. Pedicini P, Caivano R, Jereczek‑Fossa BA, et al: Modelling the correlation expression and tumor cell radiosensitivity, and combined treatments of radiation and monoclonal antibody EGFr inhibitors. Theor Biol Med Model 9: 23, 2012.